Alzheimer's disease (AD) is the most common cause of dementia, and its prevalence will increase significantly in the coming decades. Although important progress has been made, fundamental pathogenic mechanisms as well as most hereditary contributions to the sporadic form of the disease remain unknown. In this review, we examine the now substantial links between AD pathogenesis and lysosomal biology. The lysosome hydrolyses and processes cargo delivered by multiple pathways, including endocytosis and autophagy. The endo-lysosomal and autophagic networks are central to clearance of cellular macromolecules, which is important given there is a deficit in clearance of amyloid-b in AD. Numerous studies show prominent lysosomal dysfunction in AD, including perturbed trafficking of lysosomal enzymes and accumulation of the same substrates that accumulate in lysosomal storage disorders. Examination of the brain in lysosomal storage disorders shows the accumulation of amyloid precursor protein metabolites, which further links lysosomal dysfunction with AD. This and other evidence leads us to hypothesise that genetic variation in lysosomal genes modifies the disease course of sporadic AD.
'Dementia' refers to a group of neurological conditions that interfere with cognitive function and the ability to perform everyday tasks. The World Alzheimer Report 2015 estimated the worldwide prevalence of dementia to be 46.8 million (Prince et al. 2015) . This number is predicted to increase to 74.7 million by 2030 and 131.4 million by 2050, mainly due to population growth and demographic ageing (Prince et al. 2015) . The global cost of dementia is currently estimated to be $818 billion (US dollars), rising to $2 trillion by 2030 (Prince et al. 2015 ). Alzheimer's disease (AD) is the most common form of dementia, accounting for 50-70% of latelife cases (Plassman et al. 2007 ). In the early stages of this neurodegenerative condition, patients experience impairment in episodic memory (the ability to learn and retain new information) (Wilson et al. 1983; Flicker et al. 1984) . Deficits in executive function emerge, and ultimately, patients lose the ability to communicate, respond to their environment and control movement, leading to a requirement for full-time care (Alzheimer 1906; Kraepelin 1910; Albert 2011) . There is currently no effective, disease-altering treatment for AD.
Genetic causes of sporadic AD are complex and unknown
One of the challenges in developing effective treatments and/or preventions for AD is that the pathogenic basis remains largely unknown. The most important risk factor for AD is age. The incidence of AD doubles for every 5 years after the age of 65 (Jorm et al. 1987; Ritchie et al. 1992) . Environmental risk factors also exist, including hypertension, oestrogen supplementation and smoking (Almeida et al. 2002; Patterson et al. 2008; Cataldo et al. 2010) . Other environmental factors appear to decrease the risk of developing AD, including exercise, intellectual or social stimulation and a Mediterranean diet (Lindsay et al. 2002; Wang et al. 2002; Podewils et al. 2005; Scarmeas et al. 2006; Boots et al. 2015) .
Early-onset autosomal dominant or familial forms of AD have shed some light on the genetic pathways involved in AD. These familial cases result from one of a number of mutations in the amyloid precursor protein (APP) gene, or from mutations in the in genes encoding presenilins, which make up the catalytic subunits of c-secretase, an enzyme involved in processing APP. However, these mutations are rare and only account for 1-5% of all AD cases . In addition to familial AD, Down Syndrome (DS) patients provide an unique opportunity to study AD-related processes in humans in a predictable manner (Cataldo et al. 2008) . Almost all individuals with DS develop neuropathological changes in the brain, similar to those observed in AD (Jervis 1948; Mann 1988) . Amyloid-b (Ab) deposits and tau pathology can be seen by the age of 40 (Wisniewski et al. 1985) , and clinical dementia occurs in approximately 30% of DS patients by the fifth decade of life (Mann and Esiri 1989; Prasher and Krishnan 1993) . The ADlike pathology observed in DS is due to overexpression of APP, which is on chromosome 21 and therefore present in triplicate in DS patients (Prasher et al. 1998) .
The genetic contribution towards the more common, sporadic late-onset forms of AD is less well understood. Genome-wide association studies have identified a number of loci which are associated with AD (Ridge et al. 2013) . Common genetic variations have been estimated to account for between 24% (Lee et al. 2013 ) and 33% (Ridge et al. 2013) of variance in AD. However, over 75% of this phenotypic variance is due to genes which have not yet been identified (Ridge et al. 2013) . It is expected that there are a large number of common variants with small effect sizes that remain to be found. It is also likely that many rarer genetic variants with large effects and high penetrance remain to be identified, as rare variants are unlikely to be detected using traditional genome-wide association studies (Ridge et al. 2013) . Much higher rates of heritability have been predicted in studies of monozygotic and dizygotic twins, including a study of Swedish twins, which estimated heritability of sporadic AD to be 58-79% (Gatz et al. 2006) .
Of the genetic contribution towards sporadic late-onset AD that has been identified, variation in genes that regulate early parts of the endo-lysosomal network appears to be an emerging theme. Such genes have been identified using genome-wide association analysis of large cohorts of people (Lambert et al. 2013) and include but are not limited to genes such as bridging integrator 1 (BIN1), PICALM and CD2-associated protein. How variation in these and other genes contributes to AD pathogenesis is an area of intense investigation. However, research already shows AD-associated genetic variation could result in abnormal trafficking in the endo-lysosomal and autophagic networks (Cormont et al. 2003; Moreau et al. 2014; Miyagawa et al. 2016 ).
Generation of amyloid-b from proteolysis of amyloid precursor protein
Histologically, AD is characterised by deposition of Ab peptides in extracellular amyloid plaques in the brain and intraneuronal accumulation of tau. While tau plays an important role in AD, the remainder of this review will focus on Ab. Ab is formed, along with other protein species important to AD pathogenesis that include APP-carboxy terminal fragments (APP-CTFs), by the proteolytic processing of APP (Fig. 1) . APP can be cleaved by either a-or b-secretases. The primary a-secretase in neurons is ADAM10 (Kuhn et al. 2010) . This cleavage occurs within the Ab peptide sequence to generate a-carboxy terminal fragments (a-CTFs) and thus precludes the formation of Ab (the nonamyloidogenic pathway) (Sisodia et al. 1990 ). a-CTFs are then cleaved by c-secretase to produce a peptide fragment called P3 (Haass et al. 1992a) . Alternatively, APP can be cleaved by the bsite APP cleaving enzyme 1 (Vassar et al. 1999) to produce bcarboxy terminal fragments (b-CTFs). This is the first step of the amyloidogenic pathway and subsequent and complex cleavage events performed by the c-secretase complex yields the Ab40 and Ab42 species (Takami et al. 2009 ). Of these species, Ab42 is considered more toxic as it aggregates more effectively than Ab40 (Jarrett et al. 1993 ). This effect drives many cases of earlyonset familial AD. Pathogenesis in the large majority of dominantly inherited early-onset familial AD cases (caused by mutations in the presenilin genes that impact c-secretase function) is thought to arise from a change in the balance of Ab species, favouring an increase in the Ab42/Ab40 ratio (Ch avez-Guti errez et al. 2012; Fernandez et al. 2014; Sannerud et al. 2016) . The increase in Ab42 drives increased Ab aggregation, which may also impact its clearance.
Vesicular transport of APP and its metabolites in the endo-lysosomal network
The endo-lysosomal and autophagic networks are critical for APP metabolism. The endo-lysosomal network incorporates a number of communicating vesicular compartments with acidic pH (4.5-6.0), which contain varying levels of acid hydrolases. This network regulates cellular homoeostasis and metabolism by the degradation of cargo that is received from the plasma membrane. The autophagic pathway sequesters cytosol and organelles for transport to and hydrolysis in the lysosome. The endo-lysosomal network is involved in both the proteolytic generation of APP-CTFs and Ab from APP (Koo and Squazzo 1994; Soriano et al. 1999; Yu et al. 2004 Yu et al. , 2005 and their complete hydrolysis (Caporaso et al. 1992; Golde et al. 1992; Haass et al. 1992b; Mueller-Steiner et al. 2006; Edgar et al. 2015) . APP, as a membrane-bound protein, is subject to vesicular transport, processing and degradation within this network. However, if APP is not cleaved in the endo-lysosomal network, it can be trafficked to the Golgi apparatus, in association with retromer, or recycled back to the plasma membrane, where it can be processed by a-secretase (Esch et al. 1990; Andersen et al. 2005) , via the non-amyloidogenic pathway.
Ab has been identified in a number of organelles within degradative pathways that lead to the lysosome, including endosomes (Cataldo et al. 2004) , autophagic vesicles , multivesicular bodies/late endosomes (Takahashi et al. 2002 (Takahashi et al. , 2004 Morel et al. 2013 ) and lysosomes (Tagawa et al. 1993; Langui et al. 2004; Liu et al. 2010) . A substantial body of evidence suggests that Ab generation occurs in endosomes (Koo and Squazzo 1994; Soriano et al. 1999; Nixon and Cataldo 2006; Small and Gandy 2006) . In support of this hypothesis, b-secretase has optimal activity at mildly acidic pH and co-localises with APP in endosomal, but not lysosomal compartments (Haass et al. 1993; Huse et al. 2000; Kinoshita et al. 2003) . b-secretase is recycled from endosomes to the plasma membrane, where it can be re-endocytosed to replenish the pool of b-secretase in early endosomes (Udayar et al. 2013) . Interference with this pathway reduces the production of Ab and soluble amyloid precursor protein beta (sAPPb), indicating that localisation of b-secretase in early endosomes is required for Ab generation (Udayar et al. 2013) . Furthermore, APP-CTFs have been found in endosomes, and a mutant form of APP which remains in endosomes rather than being sorted into intraluminal vesicles is more extensively processed through the amyloidogenic pathway (Morel et al. 2013) . There is also evidence that Ab is principally localised in Rab5-positive endosomes in neurons from human AD and DS brain (Cataldo et al. 2004) . The steady-state localisation and processing of APP in endosomes are consistent with the hypothesis that any APP that reaches the lysosome is rapidly degraded Xiao et al. 2015) .
In addition, subcellular fractionation experiments have shown that APP is a component of the outer lysosomal membrane and demonstrated the presence of c-secretase activity in lysosomal membranes (Pasternak et al. 2003) . The same study reported a pH optimum of 4.5 for c-secretase, which is expected for a lysosomal enzyme (Pasternak et al. 2003) . Consistent with lysosomal processing of APP, livecell imaging in a mouse neuroblastoma cell line (SN56) has shown rapid trafficking of APP from the Golgi apparatus to the lysosome, and accumulation of APP in lysosomeassociated membrane protein 1-positive lysosomes following specific inhibition of c-secretase (Tam et al. 2014) .
It is likely that multiple organelles within the endolysosomal and autophagic networks are involved in APP metabolism. Processing of APP and the production of Ab in different organelles within these networks is consistent with the intracellular distribution of distinct c-secretase complexes. An important study conducted by Sannerud et al. (2016) demonstrated that two c-secretase complexes containing presenilin 1 and presenilin 2 as alternative subunits have different intracellular distributions. Presenilin 2 was found predominately in late endosomes and lysosomes, while presenilin 1 was more broadly distributed. Intriguingly, presenilin 2, present in late endosomes and lysosomes, was found to be responsible for more of the intracellular Ab, comprising a higher Ab42:Ab40 ratio, which is considered to drive AD pathogenesis (Jarrett et al. 1993; Pensalfini et al. 2014; Peric and Annaert 2015) .
APP and its metabolites are substrates for complete lysosomal hydrolysis
In addition to being a potential site of Ab production, the lysosome is responsible for complete hydrolysis of APP, APP-CTFs and Ab (Cole et al. 1989 (Cole et al. , 1992 Boland et al. 2010; Saido and Leissring 2012; Xiao et al. 2015) . Edgar et al. (2015) reported ubiquitination and localisation of APP to the intraluminal vesicles of a subset of multivesicular bodies and delivery to the lysosome for degradation. The authors concluded that APP was rapidly degraded in the lysosome, because it was only detected in lysosomes following inhibition of lysosomal degradation. APP-CTFs also accumulate when lysosomal function is impaired in vitro (Boland et al. 2010) . A recent study highlighted the importance of lysosomal degradation of APP in preventing its amyloidogenic processing. Increasing the lysosomal degradation of APP in APP/PS1 mice, by enhancing lysosomal activity with the transcription factor EB, was able to reduce the amount of APP available for cleavage by secretase enzymes, thereby reducing the amount of APPCTFs and Ab generated (Xiao et al. 2015) . Importantly, this resulted in decreased Ab levels in brain interstitial fluid and attenuated amyloid deposits. This study highlighted the therapeutic potential of increasing lysosomal activity for enhanced clearance, especially given that during sporadic late-onset Alzheimer's disease, there is a deficit in the clearance of Ab (Mawuenyega et al. 2010 ).
The endo-lysosomal network is deregulated in AD
Given the involvement of the endo-lysosomal network in APP metabolism and Ab generation, it is perhaps not surprising that perturbance of this pathway has been reported in conjunction with AD (Peric and Annaert 2015) . Reported disruptions to the endo-lysosomal and autophagic networks are summarised in Fig. 2 . Research from the Nixon laboratory has characterised extensive endosomal pathology in AD. Fig. 2 Pathological changes in the endolysosomal and autophagic networks in Alzheimer's disease. In a normal physiological context (a), endosomes form (i), receive lysosomal enzymes from Golgi apparatusderived M6PRs (ii) and eventually fuse with or mature into lysosomal organelles (iii) where cargos are destroyed by hydrolysis. Input is also received from autophagosomes (iv) and endosomes. In Alzheimer's disease (b), network-wide changes manifest in a number of ways. Endocytosis is elevated (i) and increased M6PRs are found in the endosomal network (ii). This is accompanied by an increase in cathepsin D in early endosomes. Increases in endocytosis cause accumulation of endosomal cargoes (iii) and reduced lysosomal function causes autophagosomal cargo accumulation (iv). The lysosomes themselves accumulate more undegraded contents.
They have consistently reported increases in endosomal size in human AD brain, but not in normal aged brains (Cataldo et al. 1997 (Cataldo et al. , 2000 (Cataldo et al. , 2004 . Importantly, endocytic and lysosomal pathology is likely to occur in the very early stages of AD. It has been observed in cognitively normal individuals with neuropathological evidence of early-stage AD, who would have been expected to develop AD pathology based on stereotypic spread of disease hallmarks (Braak and Braak 1991; Mirra et al. 1993) . Such individuals exhibit endolysosomal network pathology in brain regions which do not yet have local Ab or tau pathology (Cataldo et al. 2000) . The appearance of enlarged endosomes coincides with initial increases in soluble Ab40 and Ab42 peptides (Cataldo et al. 2004) . There is some evidence from in vitro studies that the endosomal pathology may actually contribute to increased bprocessing of APP. Overexpression of rab5 in vitro replicates the increases in endosomal size and endocytic uptake observed in AD and is sufficient to increase the levels of b-CTFs and increase secretion of Ab40 and Ab42 (Grbovic et al. 2003) .
The morphological changes observed in endosomes in human AD brain are replicated in human DS brain and DS fibroblasts (Cataldo et al. 2008; Jiang et al. 2010) , as well as the segmental trisomy 16 (Ts65Dn) mouse model of DS Salehi et al. 2006) . Two key studies in DS fibroblasts have helped to elucidate the mechanisms of endosomal enlargement (Cataldo et al. 2008; Jiang et al. 2010) . Cataldo et al. (2008) provided evidence that early endocytic pathway activation plays a key role in driving endosomal enlargement. As in human AD brains, endocytic activity is increased in DS fibroblasts. Receptor-mediated endocytosis and fluid phase uptake (measured by transferrin/ epidermal growth factor uptake and incubation with horseradish peroxidase, respectively) were both increased in DS fibroblasts. Increased expression of rab4 and rab5 was also observed, which is consistent with increased endocytic uptake and recycling. Furthermore, blocking endocytosis with a guanosine triphosphate (GTP)-binding deficient rab5 mutant partially reversed endosomal enlargement in DS fibroblasts, suggesting that alterations in endocytosis may be critical for the development of endosomal pathology (Cataldo et al. 2008) .
A second study using DS fibroblasts provided evidence that b-CTFs (rather than Ab) are responsible for the morphological changes observed in endosomes in AD (Jiang et al. 2010) . Inhibition of c-secretase, which reduced Ab secretion and increased APP-CTFs without affecting APP levels, was sufficient to induce AD-like endosomal pathology in control fibroblasts. Overexpression of b-CTFs had a similar effect. Importantly, reducing the level of b-CTFs in DS fibroblasts was sufficient to reduce the size of early endosome antigen 1 (EEA1)-positive endosomes (Jiang et al. 2010) . The actions of b-CTFs in this respect have recently been shown to be mediated by the binding partner and effector of rab5, APPL1 (adaptor protein-containing pleckstrin homology domain, phosphotyrosine binding domain, and leucine zipper motif) (Kim et al. 2016 ).
Endo-lysosomal and autophagic network organelles accumulate at amyloid plaques in AD In addition to substantial endosomal pathology, increases in the number and size of other degradative pathway vesicles have been reported in AD brain (Suzuki and Terry 1967; Cataldo et al. 1996 Cataldo et al. , 2008 Yang et al. 2011) . Lysosomal hydrolases are found extracellularly, co-localising with amyloid plaques (Bernstein et al. 1989; Cataldo and Nixon 1990; Cataldo et al. 1991 Cataldo et al. , 1996 . In addition, extracellular amyloid plaques are surrounded by dystrophic neurites that are enriched in lysosomal-like organelles (Cataldo et al. 1996; Condello et al. 2011) , which are a mixture of autophagosomes, amphisomes, and autolysosomes (Nixon et al. 2005) . Importantly, the accrual of these vesicles inside axons that contact amyloid plaques occurs from the earliest stage of Ab deposition (Gowrishankar et al. 2015 ). An elegant study from the Coleman laboratory (Adalbert et al. 2009 ) demonstrated axonal dystrophy could be seen at amyloid plaques from very early in disease progression. Some of the first amyloid plaques observed were proximal to dystrophic axons, and the authors postulated that axonal transport was partially blocked. Furthermore, Lee and colleagues demonstrated that accumulation of autophagic vesicles in axons was a failure of retrograde axonal transport that was somehow functionally linked to a deficit in lysosomal function (Lee et al. 2011) , placing lysosomal activity at the centre of a prominent pathological feature in AD.
The recent study conducted by Gowrishanker and colleagues has improved our understanding of this phenomenon by detailing the composition of vesicles that accumulate around amyloid plaques in AD mouse models (Gowrishankar et al. 2015) . The majority of these organelles resided within swollen neuronal axons that contact the amyloid plaques. The abundance of LAMP1 staining Gowrishankar et al. (2015) described around the plaque on accumulating vesicles is consistent with work showing autophagic vesicles acquire LAMP1 (from fusion with late endosomes and lysosomes) early in their maturation and transport along the axon to the neuronal cell body (Maday et al. 2012) . The vesicles in these swollen axons were distinguished from lysosomes in neuronal cell bodies in that they only contained low levels of the lysosomal proteases cathepsins B, D and L. Curiously, the organelles that occupied axonal dystrophies that surrounded plaques did contain progranulin, a protein whose gene is strongly genetically linked with both lysosomal storage disorders and late-onset neurodegeneration. Gowrishankar et al. (2015) also identified a subpopulation of organelles with similar properties in the distal neuronal compartments of physiologically normal mouse brains and cultured cortical neurons. They therefore hypothesised that there was a block in the retrograde transport and maturation of these otherwise naturally occurring organelles in AD, consistent with previous observations (Lee et al. 2011) . Gowrishankar et al. (2015) postulated the LAMP1-positive vesicles were immature lysosomal precursors. However, they also have properties consistent with previously described endo-lysosomal and autophagic network vesicles such as amphisomes and multivesicular bodies/late endosomes, making it difficult to definitively categorise them at this stage.
Interestingly, b-site APP cleaving enzyme 1, the enzyme responsible for initiating b-cleavage of APP, is enriched in the vesicles that accumulate at amyloid plaques (Kandalepas et al. 2013; Gowrishankar et al. 2015) . As b-secretase is normally degraded in organelles that have fused with the lysosome, this accumulation may be a consequence of the lack of lysosomal proteases present in this abnormally accumulating group of vesicles. The accumulation of bsecretase may also further drive disease progression, by promoting production of Ab (Gowrishankar et al. 2015) .
Mis-trafficking of proteins through the endolysosomal network in AD
Further evidence of lysosomal dysfunction in AD comes from reports of alterations in lysosomal proteins. Altered expression and activity of a number of lysosomal proteins have been reported in association with AD (Table 1) . The Niemann-Pick type C1 protein, which mediates trafficking of cholesterol from lysosomes to other organelles, is elevated in patient with AD hippocampal and cortical tissue, as well as in the hippocampus of APP Swe/PSEN1dE9 mice (Kagedal et al. 2010) . Activities of the lysosomal glycohydrolases, bgalactosidase, b-hexosaminidase and a-mannosidase are increased in skin fibroblasts from patients with AD and presymptomatic individuals with familial AD mutations (Emiliani et al. 2003; Pitto et al. 2005) . b-galactosidase and b-hexosaminidase activities are also increased in the cortex of the TgCRND8 (APP KM670/671NL, V717F) mouse model of AD (Magini et al. 2015) . Similarly, cathepsin D and b-hexosaminidase A are elevated in neurons from human patients with AD (Cataldo et al. 1996) . Cathepsin D is also elevated in DS patient fibroblasts (Cataldo et al. 2008) .
However, there are also reports of lysosomal enzymes being decreased in association with AD. Glucocerebrosidase levels and activity are reduced in AD patient hippocampal tissue (Choi et al. 2015) . Cathepsin D has been reported to be decreased in skin fibroblasts from patients with AD (Urbanelli et al. 2008) , and in the hippocampus of the PS1M146L/APP751sl mouse model (Torres et al. 2012) . Hippocampal tissue from PS1M146L/APP751sl mice also has reduced levels and activity of cathepsin B (Torres et al. 2012) . Consistent with this observation, increasing cathepsin B expression has been shown to reduce Ab levels (MuellerSteiner et al. 2006; Wang et al. 2012) . In addition, enhancing lysosomal cathepsin activities by genetically deleting cystatin B, an endogenous inhibitor of lysosomal cysteine proteases, reduces disease burden in TgCRND8 mice (Yang et al. 2011) . Enhancement of lysosomal activity in TgCRND8 mice was sufficient to prevent lysosomal enlargement in these mice, reduce intracellular and extracellular Ab, and slow the development of memory and learning deficits (Yang et al. 2011) .
Altered secretion of lysosomal enzymes may, in part, explain the apparent conflict between observations that increases in several lysosomal enzymes are associated with AD on the one hand, and studies that report the enhancement of lysosomal enzyme activity being capable of reducing disease burden, on the other. The lysosomal enzyme cathepsin D is elevated in the CSF in patients with AD (Schwagerl et al. 1995) , as is lysosome-associated membrane protein 2 (Armstrong et al. 2014) . Similarly, cathepsin D, LAMP1, and ubiquitylated proteins are elevated in brain-derived blood exosomes of patients with AD compared with controls. Elevations were present one to 10 years prior to diagnosis and were sustained once clinical signs developed (Goetzl et al. 2015) . Blood plasma is another extracellular fluid in which the activity of lysosomal enzymes has been reported to be elevated in patients with AD. Patients with AD have increased bgalactosidase and b-hexosaminidase activity in blood plasma (Tiribuzi et al. 2011) . Conversely, the activity of these enzymes, as well as that of a-mannosidase, within peripheral blood mononuclear cells is decreased, indicating that there may be greater secretion of these lysosomal enzymes into the extracellular milieu (Tiribuzi et al. 2011) . These studies provide evidence that although some lysosomal enzymes may be elevated during AD, they may not be in the location required to fulfil their normal function.
In addition to enhanced secretion of lysosomal enzymes and subsequent localisation in the extracellular space, there are also reports of altered intracellular trafficking of lysosomal enzymes, and other proteins that transit through the endo-lysosomal network, in association with AD. Lysosomal cathepsins B, D, H and L, together with protease inhibitors cystatins a and b, have been shown to be differentially distributed in human AD hippocampal tissue (Nakamura et al. 1991; Ii et al. 1993) . Levels of cathepsins B and D are increased in neuronal endosomes of patients with AD, in association with increased expression of the cation-dependent mannose-6-phosphate receptor (Cataldo et al. 1997) . In an attempt to elucidate the molecular mechanism of the mislocalisation, Mathews et al. (2002) overexpressed the cationdependent mannose-6-phosphate receptor in vitro and found this to be sufficient to partially re-distribute cathepsin D from lysosomes to early endosomes, and to increase the secretion of Ab40 and Ab42.
Furthermore, although many studies show increases in amount of lysosomal enzyme or even activity, results must still be interpreted with some caution. In cell and mouse models of familial AD where presenilin 1 is genetically manipulated, impaired lysosomal function has been postulated to result from deficient lysosomal calcium storage/ release (Coen et al. 2012) or poor lysosomal acidification (Lee et al. 2010) . If either of these phenomena occur more widely in Alzheimer's disease, lysosomes may be deficient in activity even though in vitro measurements (performed using solutions buffered at optimal pH) show no change or even higher activity readings in homogenised samples. For example, reductions in enzyme activity in situ when total enzyme amounts hold similar have been demonstrated in a cell model of Alzheimer's disease (Xue et al. 2014) . Recent research has also shown some physiologically normal lysosomes ('terminal storage lysosomes') contain hydrolases but maintain a neutral internal pH and lack hydrolase activity in situ (Bright et al. 2016 ).
AD brain tissue from patients and mouse models shows accumulation of lysosomal substrates
Alterations in activity and trafficking of lysosomal enzymes are likely to be associated with altered levels of lysosomal substrates. Ab, itself a lysosomal substrate, accumulates in the lysosome earlier than it appears in extracellular amyloid plaques in an APP transgenic mouse model of AD (Shie et al. 2003) , as well as in human AD brains (D'Andrea et al. 2001) . It has been hypothesised that insoluble aggregates of Ab may actually form within the lysosome and appear extracellularly following cell death (D'Andrea et al. 2001 ). An alternative hypothesis is that Ab may be formed in the endo-lysosomal network and secreted via exosomes (Rajendran et al. 2006) or via exocytosis. In addition, LC3-II, which is normally rapidly degraded by lysosomes, accumulates in autophagic vacuoles and lysosomes of TgCRND8 mice (Yang et al. 2011) .
Gangliosides, which are lysosomal substrates, are also altered in AD (Table 2) . In most studies to date, the monosialogangliosides are reported to increase in AD, while the more Choi et al. (2015) complex trisialo-gangliosides tend to decrease. Elevated GM2 and GM3 gangliosides have been reported in the cortex of patients with AD (Kracun et al. 1991; Molander-Melin et al. 2005; Gylys et al. 2007) , where (at least for GM2) it appears to be localised in detergent-resistant membranes (MolanderMelin et al. 2005) . The total amount of GM1 is decreased in the cortex of patients with AD (Kracun et al. 1991 (Kracun et al. , 1992 , but there is a relative increase in GM1 in amyloid-positive synaptosomes and detergent-resistant membranes (Molander-Melin et al. 2005; Gylys et al. 2007 ). Other gangliosides, including GD1a, GT1b, and GD1b, are decreased in human AD brain (Kracun et al. 1991 (Kracun et al. , 1992 Taki 2012) . A number of studies have also measured brain gangliosides in mouse models of AD (Table 2 ). These studies have consistently reported elevations in GM1, GM2, GM3, GD1a, and GD3, with decreases in GT1a, GT1b, and GT3 (Barrier et al. 2007; Ariga et al. 2010; Chan et al. 2012; Yang et al. 2014 ). The exception is in models which are generated purely by presenilin mutations, as these mice appear to have decreased GM2 and GM3 (Barrier et al. 2007) . The reason for differences in these models is not clear, but presenilins have a role in the lysosome that may be separate from their role in the csecretase complex (Esselens et al. 2004; Wilson et al. 2004; Lee et al. 2010; Coen et al. 2012) , which could account for the discrepancy.
The elevated b-processing of APP during AD may contribute to alterations in gangliosides, as amyloid precursor intracellular domain, the product released along with Ab, following cleavage of b-CTFs by c-secretase, down-regulates GD3-synthase expression (Grimm et al. 2012) . There is also evidence that alterations in ganglioside levels may actually contribute to disease progression, raising the possibility that the relationship between gangliosides and AD is bi-directional. Inhibition of glucosylceramide synthase, which catalyses the first step in glycosphingolipid biosynthesis, in vitro, was found to reduce secretion of APP and Ab. It is likely that a decrease in gangliosides is responsible for this reduced amyloidogenic processing of APP, as elevations in b-CTFs were observed after the addition of exogenous gangliosides (Tamboli et al. 2005) .
GM1 and GM3 are both capable of binding Ab (Grimm et al. 2012; Calamai and Pavone 2013; Hong et al. 2014) . Barrier et al. (2007) These interactions appear to occur early in disease progression, as ganglioside-bound Ab has been detected in brains that show only the earliest signs of AD pathology (Yanagisawa et al. 1995; Yanagisawa and Ihara 1998; Hong et al. 2014) . It has been hypothesised that ganglioside-bound Ab is an endogenous seed for the formation of amyloid plaques (Hayashi et al. 2004; Ueno et al. 2014) . Furthermore, interactions between gangliosides and Ab may drive the accumulation of gangliosides, as enzymatic turnover of GM3 is strongly reduced when GM3 is bound to Ab (Grimm et al. 2012) . Additional evidence that gangliosides may contribute to disease progression in AD comes from a study which found that knockout of GD3 synthase, the enzyme responsible for synthesis of b-and c-series gangliosides, in an AD mouse model rescued impairments in reference memory tasks and reduced Ab, as well as associated neuropathology (Bernardo et al. 2009 ). However, GM1 has been found to improve memory and cognition when injected in rats alongside Ab40 (Yang et al. 2013) or Ab42 (Kreutz et al. 2013) , raising the possibility that GM1 may actually be protective. It is unclear whether endogenous GM1 would be capable of playing a protective role once Ab aggregates though, as Ab aggregates are thought to sequester GM1, which is likely to prevent it from fulfilling its physiological functions (Calamai and Pavone 2013) .
We have outlined above, a number of perturbations to the endo-lysosomal and autophagic networks in AD. Importantly, these degradative pathways suffer from mistrafficking of lysosomal enzymes, which would lead to dysfunctional clearance of substrates. This is observed through the accumulation of autophagosomes and gangliosides. The accumulation of these substrates may further drive disease progression, making the augmentation of lysosomal activity a promising therapeutic strategy.
Lysosomal storage disorders exhibit accumulation of APP metabolites
Consequences of the accumulation of lysosomal substrates, including gangliosides, can be explored by a consideration of lysosomal storage disorders (LSDs). LSDs are a group of about 50 metabolic disorders that arise from the deficiency of an enzyme or other protein required for lysosomal function (Filocamo and Morrone 2011) . This leads to intralysosomal accumulation of undegraded or partially degraded substrate, resulting in cellular dysfunction and clinical abnormalities. LSDs have a reported combined prevalence of 1 in 7700 in Australia (Meikle et al. 1999) . However, there is growing evidence that this may be an under-estimate, particularly for later onset forms (Spada et al. 2006; Duffner et al. 2009; Hwu et al. 2009; Lin et al. 2009; Wassif et al. 2016) . For example, the published incidence of the LSD Krabbe disease is approximately 1 in 100 000 (Tappino et al. 2010) , but newborn screening has revealed the number of individuals with reduced enzyme activity may be closer to 1 in 20 000, potentially reflecting a significant under-ascertainment of later onset diagnoses (Duffner et al. 2009) . Similarly, newborn screening has revealed a higher incidence of late-onset Fabry disease than previously reported (Spada et al. 2006; Hwu et al. 2009; Lin et al. 2009 ).
The clinical symptoms of LSDs are varied, and while not all LSDs involve central nervous system pathology, many have a severe neurodegenerative phenotype. The neuronal ceroid lipofuscinoses (NCL or Battens' disease), for example, are LSDs caused by loss of function mutations that result in an early-onset neurodegenerative disorder associated with congenital cognitive dysfunction, or a juvenile neurodegenerative NCL subtype associated with dementia (Siintola et al. 2006) . The brain is the most severely affected organ in a number of LSDs, reflecting the heavy reliance of neurons on lysosomal function (Wraith 2004) . While the lysosome is of critical importance to the normal physiological function of all cells, neurons are especially susceptible to its dysfunction. Neurons are terminally differentiated and do not divide. This means cellular debris cannot be divided and diluted: a human neuron must competently regulate its internal environment for 80 years or more. Compared to other cells, neurons also face physiological challenges related to their extraordinary size and polarisation. In a neuron, mature lysosomes reside within the neuronal soma and hydrolyse cargo that it perpetually receives from potentially metres worth of neurites (Gowrishankar et al. 2015) . The neuronal endolysosomal and autophagic networks must therefore be incredibly efficient and we hypothesise any perturbation to this efficiency will be detrimental over time.
Several studies have identified common neuropathological features that are shared between AD and LSDs (Orth and Mundegar 2003; Jin et al. 2004) . These studies highlight the importance of the lysosome in central nervous system function, but also suggest that lysosomal dysfunction may be capable of leading to the kind of neurodegeneration and dementia observed in AD. NCL autopsy material, representing four different subtypes of this disease, showed increased APP immunoreactivity in brain (Wisniewski et al. 1990a) . Further, differential staining patterns have been revealed using antibodies reactive towards various epitope domains of APP, suggesting that APP processing is defective in NCL (Wisniewski et al. 1990b) . Niemann-Pick type C (NPC) disease is an LSD in which cholesterol is mis-trafficked and accumulates in the endo-lysosomal network (Pentchev et al. 1985; Sokol et al. 1988) . Patients experience progressive neurodegeneration and the development of neuropathological lesions similar to those observed in AD, including the accumulation of Ab and b-CTFs (Jin et al. 2004) . Furthermore, endosomal abnormalities similar to those observed in AD are observed in NPC, together with the redistribution of cathepsin D to early endosomes (Jin et al. 2004) . The increased number of endosomes observed in AD has also been reported in Pompe's disease (Orth and Mundegar 2003) , an LSD that arises from a deficiency in acid maltase, resulting in lysosomal glycogen accumulation (Hers 1963) .
The accumulation of Ab and APP-CTFs is one of the defining features of AD and is observed in multiple of LSDs. In addition to NPC, elevated APP-CTFs and Ab have been found in the brains of mouse models of the neurodegenerative LSDs GM1 gangliosidosis and Sandhoff disease (Boland et al. 2010; Keilani et al. 2012) . Both of these disorders arise from the inability of lysosomes to degrade gangliosides and their consequent storage. The Sandhoff mouse model also exhibits phospho-tau-like immunoreactivity and has increased levels of Ab40 and Ab42 peptides in lipid-associated brain fractions (Keilani et al. 2012) . The mouse models of mucopolysaccharidosis IIIB (Ohmi et al. 2011 ) and the neuropathic form of Gaucher disease (Xu et al. 2014 ) also accumulate Ab. Accumulation of APP and APP-CTFs in the hippocampus of Neu1-deficient mice, a model of the LSD sialidosis, has also been demonstrated (Annunziata et al. 2013) . Following processing into Ab42 in the lysosomal compartment, the Ab peptides were excessively exocytosed by lysosomes in affected mice. Importantly, the amyloid plaque burden could be improved in 5XFAD AD mice when NEU1 was over-expressed via intracranial injection of gene therapy vectors (Annunziata et al. 2013) . All of the LSDs mentioned in this paragraph accumulate gangliosides, but at this stage it is not clear whether the accumulation of products of b-cleavage of APP in these models result from the increased gangliosides, lysosomal dysfunction generally or some other factor.
Does genetic heterogeneity in lysosomal genes account for phenotypic variation in AD?
Most known LSDs are inherited in an autosomal recessive manner, with the exception of Fabry, Hunter and Danon diseases, which are X-linked (Beebe and Formel 1954; Wise et al. 1962; Nishino et al. 2000) . Historically, individuals that are heterozygous for an LSD mutation have been considered asymptomatic carriers of the disease-causing allele. However, heterozygotes have reduced enzyme activity compared with normal controls, and there is now a substantial body of evidence suggesting heterozygotes may experience some pathophysiology, often at a later stage of life. Females that are heterozygous for mutations that cause Fabry disease, for example, have a significant disease burden and impaired quality of life (Wang et al. 2007) . Similarly, individuals that are heterozygous for a mutation in glucocerebrosidase (the enzyme affected in Gaucher disease) have an increased age-specific risk for Parkinson's disease compared with control individuals (Alcalay et al. 2014) , as well as earlier onset and higher disease severity scores (Nalls et al. 2013) . Even more extreme examples can be found for frontotemporal dementia. Mutations in the gene that encodes progranulin (PGRN) cause an LSD when in homozygosity (or compound heterozygosity) (Smith et al. 2012) . These mutations cause frontotemporal dementia when in heterozygosity, showing haploinsufficiency for this lysosomal protein, and implicating the lysosome in causation of a late-onset neurodegenerative disease (Benussi et al. 2008; Yu et al. 2010) . Furthermore, lysosomal storage material has recently been identified in frontotemporal dementia caused by mutations in the endo-lysosomal network gene CHMP2B (Clayton et al. 2015) . Similar storage material was also seen in neurons from people who had AD, further indicating deficit in lysosomal function in this disease.
Given the common pathological features shared between a number of LSDs and AD, we hypothesise there may be a predisposition to AD for carriers of mutations in LSD genes. A small study which performed genetic analysis for four LSD genes in human brain autopsies found an association between AD and multiple variants in the lysosomal genes GBA, SMPD1 and MCOLN1 (Clark et al. 2015) . Di Fruscio et al. (2015) recently revealed that deleterious mutations within the endo-lysosomal and autophagic networks are prevalent within the general human population. This study, which characterised a new exome-sequencing platform, even found homozygous null alleles in humans. These data predict significant functional variation in the human endo-lysosomal and autophagic networks. This genetic variation, together with the central role these networks play in AD pathogenesis and genetic observations taken from other proteinopathies lead us to hypothesise that genetic variation that affects lysosomal function accounts for phenotypic variation in AD.
Conclusion
AD is an increasingly common neurodegenerative disease, the causes of which are still not fully understood. There is increasing evidence that multiple facets of the endolysosomal and autophagic networks are disrupted in AD, and much of this disruption is observed very early in disease progression. In addition, an increasing number of studies in LSDs are describing AD-like pathology arising as a result of genetic deficiency in lysosomal function. Collectively, this suggests that there may be a bi-directional relationship between the endo-lysosomal and autophagic networks and AD. We therefore consider that lysosomal dysfunction should be investigated as a potential risk factor for AD.
